본문 바로가기

보유기술

연구성과

강스템바이오텍은 세포치료제와 오가노이드 기반 플랫폼 기술을 중심으로 과학적 검증과 임상적 가능성을 동시에 갖춘 혁신 치료제를 개발하고 있습니다.

R&D Achievements

2025.02
Primed Mesenchymal Stem Cells by IFN-γ and IL-1β ameliorate Acute Respiratory Distress Syndrome through enhancing homing effect and immunomodulation
Journal : Biomolecules & Therapeutics
2024.05
Guidelines for Manufacturing and Application of Organoids: Skin
Journal : International Journal of Stem Cells
2022.11
LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells
Journal : PLOS ONE
2021.12
Immunomodulatory effect of epidermal growth factor secreted by human umbilical cord blood-derived mesenchymal stem cells on atopic dermatitis
Journal : International Journal of Stem Cells
2021.10
Combined Mesenchymal Stem Cells and Cartilage Acellular Matrix Injection Therapy for Osteoarthritis in Goats
Journal : Tissue Eng Regen Med
2021.08
Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
Journal : Stem Cell Research & Therapy
2020.12
Extracellular Vesicles from SOD3-Transduced Stem Cells Exhibit Improved Immunomodulatory Abilities in the Murine Dermatitis Model
Journal : Antioxidants (Basel)
2020.12
Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response
Journal : Biomedicine & Pharmacotherapy
2020.09
Combinatorial Strategies for Long-term Control of Human Immunodeficiency Virus Infection
Journal : AIDS Reviews
2020.08
Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells
Journal : Stem Cell Reviews and Reports

Company

About Us

인사말
비전 및 미션
연혁
오시는 길

Business

줄기세포 치료제

오가노이드

CDMO 사업

헬스&뷰티 사업

R&D

보유기술

Investors

공지사항

IR

PR